Zoetis Inc. (NYSE:ZTS) Shares Sold by Unisphere Establishment

Unisphere Establishment lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.6% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 4,475,000 shares of the company’s stock after selling 75,000 shares during the quarter. Zoetis comprises about 7.8% of Unisphere Establishment’s portfolio, making the stock its 3rd largest holding. Unisphere Establishment’s holdings in Zoetis were worth $775,786,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of ZTS. Price T Rowe Associates Inc. MD lifted its stake in shares of Zoetis by 31.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after buying an additional 3,244,074 shares during the last quarter. Sarasin & Partners LLP raised its stake in Zoetis by 546.3% in the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after purchasing an additional 1,904,899 shares in the last quarter. Swedbank AB acquired a new stake in Zoetis in the 1st quarter worth about $210,815,000. Public Employees Retirement Association of Colorado acquired a new stake in Zoetis in the 4th quarter worth about $242,757,000. Finally, Marshall Wace LLP raised its stake in Zoetis by 7,608.6% in the 2nd quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock worth $144,874,000 after purchasing an additional 824,843 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Piper Sandler lifted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research lifted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Stifel Nicolaus lifted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $220.38.

Zoetis Price Performance

ZTS stock opened at $193.68 on Wednesday. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The firm has a market cap of $87.75 billion, a P/E ratio of 37.32, a P/E/G ratio of 2.97 and a beta of 0.88. The company’s 50-day moving average price is $185.22 and its two-hundred day moving average price is $174.50.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period last year, the firm earned $1.41 EPS. On average, analysts anticipate that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.